Bio-Path Holdings (Nasdaq:BPTH) - Stock Price, News & Analysis

BPTH Stock Overview

Bio-Path Holdings, Inc. opera en Estados Unidos como empresa de desarrollo de fármacos basados en nanopartículas de ARNi para oncología en fase clínica y preclínica.

About the company

BPTH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas se han diluido sustancialmente en el último año

No tiene una capitalización bursátil significativa ($6M)

Volatilidad del precio de la acción en los últimos 3 meses

+ 1 more risk

Bio-Path Holdings, Inc. Competitors

Oncorus

OTCPK:ONCR

US$3.3m

Quoin Pharmaceuticals

NasdaqCM:QNRX

US$3.0m

Aravive

NasdaqGS:ARAV

US$2.9m

Atreca

OTCPK:BCEL

US$2.9m

Price History & Performance

Summary of all time highs, changes and price drops for Bio-Path Holdings
Historical stock prices
Current Share Price	US$3.89
52 Week High	US$44.80
52 Week Low	US$3.51
Beta	0.38
1 Month Change	-33.28%
3 Month Change	-63.31%
1 Year Change	-86.77%
3 Year Change	-96.90%
5 Year Change	-99.06%
Change since IPO	-99.87%

Recent updates

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Nov 05

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Aug 16

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Jul 08

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Mar 24

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Aug 17

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Mar 26

Shareholder Returns

	BPTH	US Biotechs	US Market
7D	-15.4%	-4.1%	-0.7%
1Y	-86.8%	4.0%	25.9%

Rentabilidad frente al sector: BPTH obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 8.1%.

Rentabilidad vs. Mercado: BPTH obtuvo unos resultados inferiores a los del mercado US, que fue del 23.3% el año pasado.

Price Volatility

Is BPTH's price volatile compared to industry and market?
BPTH volatility
BPTH Average Weekly Movement	14.5%
Biotechs Industry Average Movement	11.9%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: BPTHha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: BPTHha disminuido de 20% a 13% en el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2007	10	Peter Nielsen	https://www.biopathholdings.com

Bio-Path Holdings, Inc. es una empresa estadounidense dedicada al desarrollo de nanopartículas de ARNi para oncología en fase clínica y preclínica. La empresa desarrolla productos basados en DNAbilize, una plataforma tecnológica de administración de fármacos y antisentido que utiliza P-etoxi, que es una modificación de la columna vertebral del ácido desoxirribonucleico (ADN) destinada a proteger el ADN de la destrucción. Su principal candidato a fármaco es el prexigebersen, que se encuentra en ensayos clínicos de fase II para el tratamiento de la leucemia mieloide aguda (LMA) y el síndrome mielodisplásico.

Bio-Path Holdings, Inc. Fundamentals Summary

How do Bio-Path Holdings's earnings and revenue compare to its market cap?
BPTH fundamental statistics
Market cap	US$3.17m
Earnings (TTM)	-US$16.08m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is BPTH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BPTH income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$16.08m
Earnings	-US$16.08m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-21.33
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did BPTH perform over the long term?

See historical performance and comparison

BPTH Stock Overview

Rewards

Risk Analysis

Bio-Path Holdings, Inc. Competitors

OTCPK:ONCR

US$3.3m

NasdaqCM:QNRX

US$3.0m

NasdaqGS:ARAV

US$2.9m

OTCPK:BCEL

US$2.9m

Price History & Performance

Recent News & Updates

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Profitability

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.29925 million.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $7.499995 million.

Recent updates

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Profitability

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.29925 million.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings, Inc. to Report Q4, 2023 Results on Mar 08, 2024

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $23.75 million.

New major risk - Share price stability

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $19 million.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia

No longer forecast to breakeven

Bio-Path Holdings, Inc. to Report Q3, 2023 Results on Nov 15, 2023

Bio-Path Holdings, Inc., Annual General Meeting, Dec 14, 2023

Bio-Path Holdings, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target decreased by 7.7% to US$12.00

Bio-Path Holdings, Inc. to Report Q2, 2023 Results on Aug 15, 2023

New major risk - Shareholder dilution

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

New major risk - Market cap size

New minor risk - Share price stability

Bio-Path Holdings, Inc. to Report Q1, 2023 Results on May 12, 2023

Forecast to breakeven in 2025

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q3, 2022 Results on Nov 15, 2022

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Bio-Path Holdings, Inc., Annual General Meeting, Dec 15, 2022

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Bio-Path Holdings, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q1, 2022 Results on May 17, 2022

Price target increased to US$12.50

Less than half of directors are independent

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc. Appoints Aline Sherwood to its Board of Directors

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Bio-Path Holdings, Inc. to Report Fiscal Year 2021 Results on Mar 11, 2022

Insufficient new directors

Bio-Path Holdings, Inc. Announces Resignation of Martina Molsbergen as Member of the Board and All Committees of the Board

Bio-Path Holdings, Inc. Presents Data from Ongoing Phase 2 Study of Prexigebersen At 2021 American Society of Hematology Annual Meeting

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$12.50

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Bio-Path Holdings, Inc. to Report Fiscal Year 2020 Results on Mar 10, 2021

New 90-day high: US$4.55

Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

Dosing underway in Bio-Path's early-stage BP1002 study

Bio-Path EPS beats by $0.07

Bio-Path Holdings, Inc. to Report Q3, 2020 Results on Nov 13, 2020

Bio-Path Holdings, Inc., Annual General Meeting, Dec 17, 2020

New 90-day low: US$3.72

New 90-day low - US$3.86